Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Inventiva said it completed June 12, 2026 steps of its EIB and new debt financing. According to the company, it repaid EIB loans in full for about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It also issued Tranche A €35m convertible bonds and Tranche B €40m amortized bonds for initial gross proceeds €75m, with net proceeds €71.3m.
Deleveraging plus fresh secured financing reduces near-term funding overhang but introduces dilution/optionality via convertible bonds and warrants.
Inventiva completed €62.2m EIB loan repayment, repurchased EIB warrants for €50m, and issued €75m new debt tranches with €71.3m net proceeds.
Likely near-term support from funding clarity, offset by dilution/warrant overhang; watch for sensitivity to conversion/exercise pricing versus recent equity levels.
Background
Inventiva previously announced a combined transaction (EIB loan repayment/warrant repurchase plus new debt tranches) contingent on completing an equity financing.
Why it matters
The company ties the EIB repayment and debt issuance to the equity offering closing, and now confirms the transaction steps are completed with specified conversion and exercise prices.
Market relevance
This is a capital-structure event: secured debt replaces EIB exposure and provides net proceeds, while convertible/warrant terms define future dilution risk.
Market effects
Biopharma clinical-stage issuers may see read-across for EIB-style secured financing structures and the market’s tolerance for dilution tied to conversion/warrants.
Supports sentiment for European small/mid-cap biopharma names with US listings when they close cross-border financing.
Limited beyond the issuer; however, it signals continued availability of structured debt financing for cash-burn biotech.
Alternative perspectives
The net proceeds are meaningful, but the conversion ratio and warrant exercise price imply future share issuance risk that can cap upside even after funding clarity.
Remaining EIB warrants require shareholder approval for cancellation; timing of the June 30, 2026 general meeting could create event-driven volatility.
Key entities
- companyInventiva
Clinical-stage biopharma developing oral therapy for MASH (lanifibranor).
- lenderEIB
European Investment Bank; loans repaid and warrants repurchased/cancelled as part of the restructuring.
- lendersBlackRock and Claret Capital Partners
Funds/accounts managing the lenders under the subscription agreement for the new debt tranches.
